Plandai Biotechnology Sets for Battle Against Neurological Diseases by using Nutraceuticals

Plandaí­ Biotechnology, Inc. (OTCQB: PLPL) transforming the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. These extracts are utilized to deliver a new family of drugs to safely and cost effectively treats a plethora of different diseases and conditions.

Read more »

Pharma Live: Cytokinetics amending errors in Amyotrophic Lateral Sclerosis Phase IIB Study

Cytokinetics (CYTK) is a clinical stage biotechnology company that focuses on the discovery and development of novel molecular therapeutics in relation to muscle function.

Read more »

ALS TDI -The First Non Profit Biotech, A Hidden Investment Opportunity?

Strategically, the organization has done a good job in moving drugs through clinical trials but lacks venture capital funding. But the benefit investors stand to gain is a major stakehold in the drug with a low investment.

Read more »

TDI-132 shows promising results in the treatment of ALS

ALS may be the most deadly disease many people have never heard of. Also referred to as Lou Gehrig’s disease, it affects at least 30,000 people in the United States and 450,000 people worldwide.

Read more »